All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

mizoribine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
ribofuranyl-derivatives of the "pyrazofurin" type	3363	50924-49-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mizoribine bredinin beta-Bredinin	imidazole nucleoside with immunosuppressive activity isolated from culture filtrate of Eupenicillium brefeldianum; structure Molecular weight: 259.22 Formula: C9H13N3O6 CLOGP: -1.36 LIPINSKI: 0 HAC: 9 HDO: 5 TPSA: 151.06 ALOGS: -0.86 ROTB: 3

Drug dosage:

None

ADMET properties:

Property	Value	Reference
S (Water solubility)	51 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ
BA (Bioavailability)	40 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK1,PDK2,PRKDC,TEK	21
kinase-selectivity-class	GRK2,MAP2K6	2
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteonecrosis	47.94	32.24	17	1308	26224	90600898
Pharyngitis	39.25	32.24	14	1311	21933	90605189
Hyperuricaemia	36.37	32.24	10	1315	6709	90620413
Hyperlipidaemia	34.96	32.24	13	1312	22903	90604219
Iron deficiency anaemia	34.55	32.24	13	1312	23649	90603473

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypogammaglobulinaemia	49.66	42.74	15	724	11876	42608720

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypogammaglobulinaemia	49.97	27.32	18	2316	20058	110566907
Cytomegalovirus infection	41.25	27.32	21	2313	54423	110532542
Osteonecrosis	40.91	27.32	18	2316	33723	110553242
Pharyngitis	39.11	27.32	16	2318	25082	110561883
N-telopeptide urine increased	37.63	27.32	5	2329	42	110586923
Kidney transplant rejection	34.59	27.32	12	2322	11975	110574990
Diabetes mellitus	34.27	27.32	23	2311	99358	110487607
Hyperlipidaemia	33.63	27.32	16	2318	35832	110551133
Iron deficiency anaemia	32.43	27.32	15	2319	31544	110555421
Hyperuricaemia	32.34	27.32	12	2322	14519	110572446
Upper respiratory tract inflammation	32.33	27.32	9	2325	4362	110582603
Nephrogenic anaemia	31.92	27.32	9	2325	4568	110582397
Varicella zoster virus infection	28.99	27.32	9	2325	6359	110580606
Disseminated intravascular coagulation	28.60	27.32	15	2319	41271	110545694
Off label use	28.25	27.32	82	2252	1500103	109086862
Diffuse large B-cell lymphoma	27.75	27.32	11	2323	15887	110571078

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D000700	Analgesics
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000903	Antibiotics, Antineoplastic
MeSH PA	D000962	Antimalarials
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D000981	Antiprotozoal Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D007155	Immunologic Factors
MeSH PA	D007166	Immunosuppressive Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D018689	Sensory System Agents
MeSH PA	D018712	Analgesics, Non-Narcotic
CHEBI has role	CHEBI:35842	antirheumatic drug
CHEBI has role	CHEBI:67079	anti-inflammatory agent
CHEBI has role	CHEBI:149553	anticoronaviral agent

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.79	acidic
pKa2	11.55	acidic
pKa3	11.83	acidic
pKa4	12.51	acidic
pKa5	13.19	acidic
pKa6	3.13	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D01392	KEGG_DRUG
C0128608	UMLSCUI
CHEBI:31858	CHEBI
MZR	PDB_CHEM_ID
CHEMBL245019	ChEMBL_ID
DB12617	DRUGBANK_ID
C010052	MESH_SUPPLEMENTAL_RECORD_UI
104762	PUBCHEM_CID
5120	INN_ID
4JR41A10VP	UNII
772627008	SNOMEDCT_US
4JR41A10VP	INXIGHT DRUGS

Pharmaceutical products:

None